Login to Your Account

Avila Raises $30M, Pulls Down $200M Deal with Novartis Fund

By Donna Young

Tuesday, July 28, 2009
Biotech start-up Avila Therapeutics Inc. not only raised $30 million in a Series B financing, but snagged a deal potentially worth $200 million in up-front and milestones plus royalties with Novartis Option Fund. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription